Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515

RecruitingPhase 1

Sponsor: Eli Lilly and Company

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

Interventions: LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin

Countries: United States, Canada, China, France, Germany, Ireland, Italy, Japan

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
* Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA
* Have an ECOG performance status of ≤ 1
* Must have received ≥ 1 prior line of systemic chemotherapy for advanced or metastatic disease
* Participants with asymptomatic or treated CNS disease may be eligible.

Exclusion Criteria:

* Have known active CNS metastases and/or carcinomatous meningitis.
* Have any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1.
* Have significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction.
* Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.
* Have known active hepatitis B virus (HBV) and hepatitis C virus (HCV).
* Have other active malignancy unless in remission with life expectancy greater than (\>) 2 years.
Locations (52)
  • Duarte, California, United States
  • Santa Monica, California, United States
  • Denver, Colorado, United States
  • Washington D.C., District of Columbia, United States
  • Orlando, Florida, United States
  • Atlanta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Boston, Massachusetts, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Grand Rapids, Michigan, United States
  • New York, New York, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Pittsburgh, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Nashville, Tennessee, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
  • Ottawa, Canada
  • Toronto, Canada
  • Beijing, China
  • Beijing, China
  • Harbin, China
  • + 22 more on CT.gov